P25. Access to diagnostics: a bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic

K Lykopoulos; P Collins; M Hall; R Ehness; J Barth; J Louahed

首页> 外文期刊>Journal for ImmunoTherapy of Cancer >P25. Access to diagnostics: a bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic

【24h】

P25. Access to diagnostics: a bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic

机译：P25。获取诊断信息：免疫治疗发展的瓶颈-MAGE-A3癌症免疫治疗的案例

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal for ImmunoTherapy of Cancer》 |2014年第s2期|共页
作者
K Lykopoulos; P Collins; M Hall; R Ehness; J Barth; J Louahed;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. P25. Access to diagnostics: a bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic [J] . K Lykopoulos, P Collins, M Hall, Journal for ImmunoTherapy of Cancer . 2014,第S2期

机译：P25。获取诊断信息：免疫治疗发展的瓶颈-MAGE-A3癌症免疫治疗的案例
2. Nonclinical reproductive and developmental safety evaluation of the MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment [J] . Destexhe E., Stannard D., Wilby O. K., Reproductive toxicology . 2015,第Null期

机译：MAGE-A3癌症免疫治疗剂（一种用于癌症治疗的治疗性疫苗）的非临床生殖和发育安全性评估
3. 9021 Preliminary results of MAGE-A3 expression and baseline demographic data from MAGRIT, a large phase III trial of MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) in adjuvant NSCLC [J] . M.Zielinski, U.Laskowski, R.Bieselt, European Journal of Cancer Supplements . 2009,第2期

机译：9021来自MAGRIT的MAGE-A3表达和基线人口统计学数据的初步结果，MAGRIT是MAGE-A3 ASCI（抗原特异性癌症免疫治疗剂）在佐剂NSCLC中进行的大型III期试验
4. DEVELOPMENT OF IMMUNOTHERAPEUTIC IMMUNIZATION FOR VIRUS INFECTIONS AND CANCER [C] . Ian Frazer Vaccine technology VI . 2016

机译：病毒感染和癌症免疫治疗的发展
5. Development of novel immunotherapeutics against cancer. [D] . Ashour, Abdelkader Elbadawy Abbas. 2006

机译：新型抗癌免疫疗法的开发。
6. P25. Access to diagnostics: a bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic [O] . K Lykopoulos, P Collins, M Hall, 2014

机译：P25。获取诊断信息：免疫疗法发展的瓶颈-MAGE-A3癌症免疫疗法的案例
7. P25. Access to diagnostics: a bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic [O] . K Lykopoulos, P Collins, M Hall, 2014

机译：P25。获取诊断信息：免疫疗法发展的瓶颈-MAGE-A3癌症免疫疗法的案例

P25. Access to diagnostics: a bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic

著录项

相似文献

相关主题

期刊订阅